242 related articles for article (PubMed ID: 33006584)
1. PARP inhibition as frontline therapy in ovarian cancer.
Moore KN; Pothuri B; Monk B; Coleman RL
Clin Adv Hematol Oncol; 2020 Sep; 18(9):550-556. PubMed ID: 33006584
[TBL] [Abstract][Full Text] [Related]
2. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
3. PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitors in ovarian cancer.
Goldlust IS; Guidice E; Lee JM
Semin Oncol; 2024; 51(1-2):45-57. PubMed ID: 38262776
[TBL] [Abstract][Full Text] [Related]
5. Selection of maintenance therapy during first-line treatment of advanced ovarian cancer based on pharmacologic characteristics.
Nakai H; Matsumura N
Expert Opin Pharmacother; 2023; 24(18):2161-2173. PubMed ID: 38111255
[TBL] [Abstract][Full Text] [Related]
6. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy for newly and recurrent epithelial ovarian cancer: current therapies and future perspectives.
Salutari V; Giudice E; Lorusso D
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):9-17. PubMed ID: 38170548
[TBL] [Abstract][Full Text] [Related]
8. Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
Richardson DL; Eskander RN; O'Malley DM
JAMA Oncol; 2023 Jun; 9(6):851-859. PubMed ID: 37079311
[TBL] [Abstract][Full Text] [Related]
9. Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma.
Christinat Y; Ho L; Clément S; Genestie C; Sehouli J; Cinieri S; Gonzalez Martin A; Denison U; Fujiwara K; Vergote I; Tognon G; Hietanen S; Ray-Coquard I; Pujade-Lauraine E; McKee TA
JCO Precis Oncol; 2023 Jun; 7():e2200555. PubMed ID: 37364234
[TBL] [Abstract][Full Text] [Related]
10. [Current post-surgical treatment strategies in first-line ovarian cancer].
Ouali K; Michels J; Blanc-Durand F; Leary A; Kfoury M; Genestie C; Morice P; Zaccarini F; Scherrier S; Gouy S; Maulard A; Pautier P
Bull Cancer; 2024 Mar; 111(3):267-276. PubMed ID: 36863923
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
12. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
Bai H; Cao D; Yang J; Li M; Zhang Z; Shen K
J Cell Mol Med; 2016 Apr; 20(4):581-93. PubMed ID: 26800494
[TBL] [Abstract][Full Text] [Related]
13. Personalising Treatment for High-Grade Serous Ovarian Carcinoma.
Cojocaru E; Parkinson CA; Brenton JD
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):515-524. PubMed ID: 29934103
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Molnár S; Beke L; Méhes G; Póka R
Pathol Oncol Res; 2020 Oct; 26(4):2549-2555. PubMed ID: 32594311
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
O'Sullivan Coyne G; Chen AP; Meehan R; Doroshow JH
Drugs; 2017 Feb; 77(2):113-130. PubMed ID: 28078645
[TBL] [Abstract][Full Text] [Related]
16. Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey.
Kim JH; Lee Y; Kim DY; Kim S; Seo SS; Kang S; Park SY; Lim MC
J Gynecol Oncol; 2024 Jan; 35(1):e3. PubMed ID: 37681357
[TBL] [Abstract][Full Text] [Related]
17. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Scott CL; Swisher EM; Kaufmann SH
J Clin Oncol; 2015 Apr; 33(12):1397-406. PubMed ID: 25779564
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
Ledermann JA; El-Khouly F
Br J Cancer; 2015 Dec; 113 Suppl 1(Suppl 1):S10-6. PubMed ID: 26669450
[TBL] [Abstract][Full Text] [Related]
19. Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Funingana IG; Reinius MAV; Petrillo A; Ang JE; Brenton JD
Semin Cancer Biol; 2021 Dec; 77():67-82. PubMed ID: 33607245
[TBL] [Abstract][Full Text] [Related]
20. PARP inhibitors in epithelial ovarian cancer: what are their potential implications for surgical management?
Peters I; Marchetti C; Fagotti A; Scambia G
Eur J Surg Oncol; 2023 Sep; 49(9):106973. PubMed ID: 37414629
[No Abstract] [Full Text] [Related]
[Next] [New Search]